haha. With their market cap where it is , and supposedly heading, Id say they need to be paying more to get more.
Printable View
In a research note released today, Forsyth Barr gave Pacific Edge an outperform tag, with a target price of $1.60, up from its last close of $1.2 a share.
Forsyth Barr senior analyst Chelsea Leadbetter said the bladder cancer test market opportunity was extensive and Pacific Edge was well positioned to capitalise on it.
“There is no shortcut to changing clinical practice and the hard work is far from over, however, recent key milestones have helped to prove up the commercial model and lower the risk.”
https://www.nbr.co.nz/story/pacific-...ing-strong-run
Brokerage companies like Forsyth bar has also given Plexure and outperform of $1.58.. they have absolutely no clue. I'd love to see how they come up with these figures given they are both growth companies and impossible to predict new acquisitions, contracts, revenue. These types of companies could change on a dime. So far plexure has ipo'd on the asx and not brought in another customer or another announcement since.
Forsyth/Morningstar = rubbish.
I believe they used a 10 year discounted cash flow method to come to that figure. It’s not out of thin air. Of course it’s all based on an ideal growth trajectory with more and more physicians becoming confident in the efficiency and accuracy of PEBs test suits.
I think a key difference between Plexure and PEB is that it’s much harder for potential competitors to catch up to PEB whereas it might be relatively easier for Plexure’s competition to replicate or augment existing tech to create a better version to engage new mobile users.
agree with you calledone. PEB has some 10yrs advantage tech comparing with other players in this field. harder to be copied oppositing to PX1.